US5070101A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and pharmaceutical composition for the treatment of schizophrenia
Assignee: Icahn School of Medicine at Mount Sinai
•
Filing: 1991-02-14
•
Granted: 1991-12-03
•
Expires: 2011-02-14
Abstract
Abstract Persons suffering from negative symptoms of schizophrenia can be successfy treated using a histamine H 2 -antagonist which crosses the blood-brain barrier so as to interact with histamine-H 2 receptors in the brain. A preferred H 2 -antagonist is famotidine. The H 2 -antagonist may be used alone in patients who are relatively free of positive symptoms or it may be used in combination with known neuroleptics. A pharmaceutical composition containing both an H 2 -antagonist and a neuroleptic is part of the present invention.
Inventors
- 👤 Ram Kaminski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/335; A61K31/34; A61K31/41; A61K31/415; A61K31/425; A61K31/54
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
30 words
A method of treating schizophrenia comprising administering to a patient exhibiting negative symptoms of schizophrenia a therapeutically effective amount of a histamine H 2 -antagonist that crosses the blood/brain barrier.
Claim 2
Independent Claim
30 words
A method of treating schizophrenia comprising administering to a patient exhibiting negative symptoms of schizophrenia a therapeutically effective amount of a histamine H 2 -antagonist that crosses the blood/brain barrier.
Claim 3
Dependent Claim
14 words
A method according to claim 1, wherein the histamine H 2 -antagonist is famotidine.
Claim 4
Dependent Claim
23 words
A method according to claim 2, wherein the famotidine is administered orally in an amount of from 20 to 80 mg per day.
Claim 5
Dependent Claim
30 words
A method according to claim 1, wherein the histamine H 2 -antagonist is selected from the a group consisting of cimetidine, ranitidine, nizatidine, omeprazole, tiotidine, aminofurazan compounds and ORF 17578.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-02 | 1995-06-03 | 1995-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-02 | 1999-06-03 | 1999-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-02 | 2003-06-03 | 2003-12-03 | $7700.00 | Window Closed / Lapsed |